Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amylin gets full value from $7bn BMS/AZ acquisition

This article was originally published in Scrip

Executive Summary

Amylin appears to have realized full value for its Byetta/Bydureon franchise in diabetes through an acquisition by Bristol-Myers Squibb worth $31 per share, that will cost the pharma major some $7 billion, including the $1.7 billion in debt and obligations that Amylin holds. But what re-started the acquisition by BMS was the intervention by AstraZeneca to pay some $3.4 billion for certain rights to Amylin's portfolio and pipeline.

You may also be interested in...



Equillium Will Study In-Licensed Itolizumab In Three Indications In 2019

Emerging Company Profile: Equillium in-licensed the CD6 inhibitor EQ001 – Biocon's Alzumab (itolizumab), approved in India for psoriasis – and will begin clinical trials for three autoimmune disease indications this year; a Phase Ib/II aGvHD study is under way.

Gender Diversity In Pharma: Caught Between Desire And Reality

Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete. 

Women In High Places: Slow Progress In Pharma

With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.

Topics

Related Companies

UsernamePublicRestriction

Register

SC017950

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel